Download PDF
CC BY-NC-ND 4.0 · Journal of Social Health and Diabetes 2014; 02(02): 070-076
DOI: 10.4103/2321-0656.130789
Review Article
NovoNordisk Education Foundation

Pharmacological management of psychiatric disorders in pregnancy complicated by diabetics

Yatan Pal Singh Balhara
Department of Psychiatry, National Drug Dependence Treatment Centre, All India Institute of Medical Sciences, New Delhi, India
,
Rohit Verma
1   Department of Psychiatry, Lady Hardinge Medical College and SSK Hospital, New Delhi, India
,
Bharti Kalra
2   Department of Gynaecology, Bharti Hospital and B.R.I.D.E., Karnal, India
› Author Affiliations
Further Information

Publication History

Publication Date:
21 November 2018 (online)

Also available at
   Permissions and Reprints

Abstract

Pregnancy has been identified as a biological, psychological and social stressor that predisposes women to emergence/re-emergence of psychiatric disorders. Effective pharmacological treatment is available for various psychiatric disorders. However, management of psychiatric disorders during pregnancy requires careful selection of the pharmacotherapeutic agent. Management of psychiatric disorders in pregnancy among diabetics brings in an additional dimension. The psychotropic medicines have been found to impact blood glucose levels and can interfere with diabetes management. This article reviews the available evidence on the use of psychotropic medicines in antenatal women with diabetes.

Diabetes mellitus - management - psychiatric disorders - depression - anxiety - psychosocial management
 

  • References

  • 1 Lustman PJ, Griffith LS, Clouse RE, Freedland KE, Eisen SA, Rubin EH. et al. Effects of nortriptyline on depression and glycemic control in diabetes: Results of a double-blind, placebo-controlled trial. Psychosom Med 1997; 59: 241-250
    CrossrefPubMedGoogle Scholar
  • 2 Moosa MY, Panz VR, Jeenah FY, Joffe BI. African women with depression: The effect of imipramine and fluoxetine on body mass index and leptin secretion. J Clin Psychopharmacol 2003; 23: 549-552
    CrossrefPubMedGoogle Scholar
  • 3 Ghaeli P, Shahsavand E, Mesbahi M, Kamkar MZ, Sadeghi M, Dashti-Khavidaki S. Comparing the effects of 8-week treatment with fluoxetine and imipramine on fasting blood glucose of patients with major depressive disorder. J Clin Psychopharmacol 2004; 24: 386-388
    CrossrefPubMedGoogle Scholar
  • 4 Langer G, Karobath M, Sieghart W, Aschauer H, Placheta P, Spona J. Effects of antidepressant treatment with clomipramine on hormonal responses to thyrotropin-releasing hormone and insulin-induced hypoglycemia: Implications for the “monoamine-hypothesis”. Pharmacopsychiatria 1981; 14: 100-106
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Mueller PS, Heninger GR, McDonald RK. Intravenous glucose tolerance test in depression. Arch Gen Psychiatry 1969; 21: 470-477
    CrossrefPubMedGoogle Scholar
  • 6 Heninger GR, Mueller PS, Davis LS. Depressive symptoms and the glucose tolerance test and insulin tolerance test. J Nerv Ment Dis 1975; 161: 421-432
    CrossrefPubMedGoogle Scholar
  • 7 Talaei A, Siavash M, Majidi H, Chehrei A. Vitamin B12 may be more effective than nortriptyline in improving painful diabetic neuropathy. Int J Food Sci Nutr 2009; 60 (Suppl. 05) 71-76
    CrossrefPubMedGoogle Scholar
  • 8 Sindrup SH, Tuxen C, Gram LF, Grodum E, Skjold T, Brøsen K. et al. Lack of effect of mianserin on the symptoms of diabetic neuropathy. Eur J Clin Pharmacol 1992; 43: 251-255
    CrossrefPubMedGoogle Scholar
  • 9 Weber-Hamann B, Gilles M, Lederbogen F, Heuser I, Deuschle M. Improved insulin sensitivity in 80 nondiabetic patients with MDD after clinical remission in a double-blind, randomized trial of amitriptyline and paroxetine. J Clin Psychiatry 2006; 67: 1856-1861
    CrossrefPubMedGoogle Scholar
  • 10 Khazaie H, Rahimi M, Tatari F, Rezaei M, Najafi F, Tahmasian M. Treatment of depression in type 2 diabetes with Fluoxetine or Citalopram?. Neurosciences (Riyadh) 2011; 16: 42-45
    Google Scholar
  • 11 Kauffman RP, Castracane VD, White DL, Baldock SD, Owens R. Impact of the selective serotonin reuptake inhibitor citalopram on insulin sensitivity, leptin and basal cortisol secretion in depressed and non-depressed euglycemic women of reproductive age. Gynecol Endocrinol 2005; 21: 129-137
    CrossrefPubMedGoogle Scholar
  • 12 Goodnick PJ, Kumar A, Henry JH, Buki VM, Goldberg RB. Sertraline in coexisting major depression and diabetes mellitus. Psychopharmacol Bull 1997; 33: 261-264
    PubMedGoogle Scholar
  • 13 Echeverry D, Duran P, Bonds C, Lee M, Davidson MB. Effect of pharmacological treatment of depression on A1C and quality of life in low-income Hispanics and African Americans with diabetes: A randomized, double-blind, placebo-controlled trial. Diabetes Care 2009; 32: 2156-2160
    CrossrefPubMedGoogle Scholar
  • 14 Lustman PJ, Clouse RE, Nix BD, Freedland KE, Rubin EH, McGill JB. et al. Sertraline for prevention of depression recurrence in diabetes mellitus: A randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry 2006; 63: 521-529
    CrossrefPubMedGoogle Scholar
  • 15 Briscoe VJ, Ertl AC, Tate DB, Davis SN. Effects of the selective serotonin reuptake inhibitor fluoxetine on counterregulatory responses to hypoglycemia in individuals with type 1 diabetes. Diabetes 2008; 57: 3315-3322
    CrossrefPubMedGoogle Scholar
  • 16 Karabacak IY, Karabacak O, Toruner FB, Akdemir O, Arslan M. Treatment effect of sibutramine compared to fluoxetine on leptin levels in polycystic ovary disease. Gynecol Endocrinol 2004; 19: 196-201
    CrossrefPubMedGoogle Scholar
  • 17 Ye Z, Chen L, Yang Z, Li Q, Huang Y, He M. et al. Metabolic effects of fluoxetine in adults with type 2 diabetes mellitus: A meta-analysis of randomized placebo-controlled trials. PLoS One 2011; 6: e21551
    CrossrefPubMedGoogle Scholar
  • 18 Crucitti A, Zhang Q, Nilsson M, Brecht S, Yang CR, Wernicke J. Duloxetine treatment and glycemic controls in patients with diagnoses other than diabetic peripheral neuropathic pain: A meta-analysis. Curr Med Res Opin 2010; 26: 2579-2588
    CrossrefPubMedGoogle Scholar
  • 19 Chen YC, Lin WW, Chen YJ, Mao WC, Hung YJ. Antidepressant effects on insulin sensitivity and proinflammatory cytokines in the depressed males. Mediators Inflamm 2010; 2010: 573594
    PubMedGoogle Scholar
  • 20 Hennings JM, Schaaf L, Fulda S. Glucose metabolism and antidepressant medication. Curr Pharm Des 2012; 18: 5900-5919
    CrossrefPubMedGoogle Scholar
  • 21 Laimer M, Kramer-Reinstadler K, Rauchenzauner M, Lechner-Schoner T, Strauss R, Engl J. et al. Effect of mirtazapine treatment on body composition and metabolism. J Clin Psychiatry 2006; 67: 421-424
    CrossrefPubMedGoogle Scholar
  • 22 Alderman CP, Condon JT, Gilbert AL. An open-label study of mirtazapine as treatment for combat-related PTSD. Ann Pharmacother 2009; 43: 1220-1226
    CrossrefPubMedGoogle Scholar
  • 23 Lustman PJ, Freedland KE, Griffith LS, Clouse RE. Fluoxetine for depression in diabetes: A randomized double-blind placebo-controlled trial. Diabetes Care 2000; 23: 618-623
    CrossrefPubMedGoogle Scholar
  • 24 Lustman PJ, Williams MM, Sayuk GS, Nix BD, Clouse RE. Factors influencing glycemic control in type 2 diabetes during acute- and maintenance-phase treatment of major depressive disorder with bupropion. Diabetes Care 2007; 30: 459-466
    CrossrefPubMedGoogle Scholar
  • 25 Katon WJ, Von Korff M, Lin EH, Simon G, Ludman E, Russo J. et al. The Pathways Study: A randomized trial of collaborative care in patients with diabetes and depression. Arch Gen Psychiatry 2004; 61: 1042-1049
    CrossrefPubMedGoogle Scholar
  • 26 Jones GR, Lazarus JH, Davies CJ, Greenwood RH. The effect of short term lithium carbonate in Type II diabetes mellitus. Horm Metab Res 1983; 15: 422-424
    Article in Thieme ConnectPubMedGoogle Scholar
  • 27 Stephen LJ, Kwan P, Shapiro D, Dominiczak M, Brodie MJ. Hormone profiles in young adults with epilepsy treated with sodium valproate or lamotrigine monotherapy. Epilepsia 2001; 42: 1002-1006
    CrossrefPubMedGoogle Scholar
  • 28 York DA, Singer L, Thomas S, Bray GA. Effect of topiramate on body weight and body composition of osborne-mendel rats fed a high-fat diet: Alterations in hormones, neuropeptide, and uncoupling-protein mRNAs. Nutrition 2000; 16: 967-975
    CrossrefPubMedGoogle Scholar
  • 29 Addis A, Koren G. Safety of fluoxetine during the first trimester of pregnancy: A meta-analytical review of epidemiological studies. Psychol Med 2000; 30: 89-94
    CrossrefPubMedGoogle Scholar
  • 30 Cohen LS, Heller VL, Bailey JW, Grush L, Ablon JS, Bouffard SM. Birth outcomes following prenatal exposure to fluoxetine. Biol Psychiatry 2000; 48: 996-1000
    CrossrefPubMedGoogle Scholar
  • 31 McElhatton PR, Garbis HM, Elefant E, Vial T, Bellemin B, Mastroiacovo P. et al. The outcome of pregnancy in 689 women exposed to therapeutic doses of antidepressants. A collaborative study of the European Network of Teratology Information Services (ENTIS). Reprod Toxicol 1996; 10: 285-294
    CrossrefPubMedGoogle Scholar
  • 32 Ericson A, Kallen B, Wiholm B. Delivery outcome after the use of antidepressants in early pregnancy. Eur J Clin Pharmacol 1999; 55: 503-508
    CrossrefPubMedGoogle Scholar
  • 33 Kallen B, Otterblad OlaussonP. Antidepressant drugs during pregnancy and infant congenital heart defect. Reprod Toxicol 2006; 21: 221-222
    CrossrefPubMedGoogle Scholar
  • 34 Louik C, Lin AE, Werler MM, Hernandez-Diaz S, Mitchell AA. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 2007; 356: 2675-2683
    CrossrefPubMedGoogle Scholar
  • 35 Alwan S, Reefhuis J, Rasmussen SA, Olney RS, Friedman JM. National Birth Defects Prevention Study. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 2007; 356: 2684-2692
    CrossrefPubMedGoogle Scholar
  • 36 Hendrick V, Altshuler L. Management of major depression during pregnancy. Am J Psychiatry 2002; 159: 1667-1673
    CrossrefPubMedGoogle Scholar
  • 37 Nulman I, Rovet J, Stewart DE, Wolpin J, Gardner HA, Theis JG. et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 1997; 336: 258-262
    CrossrefPubMedGoogle Scholar
  • 38 Yonkers KA, Wisner KL, Stewart DE, Oberlander TF, Dell DL, Stotland N. et al. The management of depression during pregnancy: A report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Gen Hosp Psychiatry 2009; 31: 403-413
    CrossrefPubMedGoogle Scholar
  • 39 Yonkers KA, Wisner KL, Stowe Z, Leibenluft E, Cohen L, Miller L. et al. Management of bipolar disorder during pregnancy and the postpartum period. Am J Psychiatry 2004; 161: 608-620
    CrossrefPubMedGoogle Scholar
  • 40 Slone D, Siskind V, Heinonen OP, Monson RR, Kaufman DW, Shapiro S. Antenatal exposure to the phenothiazines in relation to congenital malformations, perinatal mortality rate, birth weight, and intelligence quotient score. Am J Obstet Gynecol 1977; 128: 486-488
    CrossrefPubMedGoogle Scholar
  • 41 Gentile S. Antipsychotic therapy during early and late pregnancy. A systematic review. Schizophr Bull 2010; 36: 518-544
    CrossrefPubMedGoogle Scholar
  • 42 Jacobson SJ, Jones K, Johnson K, Ceolin L, Kaur P, Sahn D. et al. Prospective multicentre study of pregnancy outcome after lithium exposure during first trimester. Lancet 1992; 339: 530-533
    CrossrefPubMedGoogle Scholar
  • 43 Kennedy D, Koren G. Valproic acid use in psychiatry: Issues in treating women of reproductive age. J Psychiatry Neurosci 1998; 23: 223-228
    PubMedGoogle Scholar
  • 44 Lanza di ScaleaT, Wisner KL. Antidepressant medication use during breastfeeding. Clin Obstet Gynecol 2009; 52: 483-497
    CrossrefPubMedGoogle Scholar
  • 45 Eberhard-Gran M, Eskild A, Opjordsmoen S. Use of psychotropic medications in treating mood disorders during lactation: Practical recommendations. CNS Drugs 2006; 20: 187-198
    CrossrefPubMedGoogle Scholar
  • 46 Stowe ZN, Hostetter AL, Owens MJ, Ritchie JC, Sternberg K, Cohen LS. et al. The pharmacokinetics of sertraline excretion into human breast milk: Determinants of infant serum concentrations. J Clin Psychiatry 2003; 64: 73-80
    CrossrefPubMedGoogle Scholar
  • 47 Franssen EJ, Meijs V, Ettaher F, Valerio PG, Keessen M, Lameijer W. Citalopram serum and milk levels in mother and infant during lactation. Ther Drug Monit 2006; 28: 2-4
    CrossrefPubMedGoogle Scholar
  • 48 Chaudron LH, Schoenecker CJ. Bupropion and breastfeeding: A case of a possible infant seizure. J Clin Psychiatry 2004; 65: 881-882
    CrossrefPubMedGoogle Scholar
  • 49 Kohen D. Psychotropic medication and breast-feeding. Adv Psychiatr Treat 2005; 11: 371-379
    CrossrefGoogle Scholar
  • 50 Barnas C, Bergant A, Hummer M, Saria A, Fleischhacker WW. Clozapine concentrations in maternal and fetal plasma, amniotic fluid, and breast milk. Am J Psychiatry 1994; 151: 945
    CrossrefPubMedGoogle Scholar
  • 51 Chaudron LH, Jefferson JW. Mood stabilizers during breastfeeding: A review. J Clin Psychiatry 2000; 61: 79-90
    CrossrefPubMedGoogle Scholar
  • 52 Miller LJ. Use of electroconvulsive therapy during pregnancy. Hosp Community Psychiatry 1994; 45: 444-450
    PubMedGoogle Scholar